Home > Insider Trading > Filing (0000903423-19-000197)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595893	Turning Point Therapeutics Inc.	TPTX	Pharmaceutical Preparations (2834)	X0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131399	Plc Glaxosmithkline	980 Great West Road Brentford Middlesex X0 TW8 9GS		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-22	1,120,730	$0.00	1,120,730	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-04-22	546,820	$0.00	1,667,550	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-04-22	325,000	$18.00	1,992,550	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2019-04-22	4,314,809	$0.00	1,120,730	$0.00
Common Stock	Series D Preferred Stock	Disposition	2019-04-22	2,105,259	$0.00	546,820	$0.00
Common Stock	Director Stock Option (right to buy)	Acquisiton	2019-04-22	15,000	$0.00	15,000	$27.06

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
15,000	2029-04-22	No	4	A	Indirect

Footnotes

S.R. One, Limited acquired 325,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The stock option was granted to Simeon George as director's compensation and will become fully vested on the date of the company's 2020 annual meeting of stockholders, subject to vesting acceleration upon a change in control of the company, and subject to the continuing service of Simeon George on each vesting date. As a Vice President of S.R. One, limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc
The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").